NCT07090486

A Study to Understand How the Use of Paxlovid Affected Healthcare Use in People With Pre-existing Conditions.

Impact of Nirmatrelvir-ritonavir on Changes in Healthcare Utilization and Frailty Following COVID-19: a Difference-in-difference Analysis

• Status: Completed
• Phase: —
• Study type: Observational
• Enrollment: 14,000 (actual)
• Sponsor: Pfizer · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This is a cohort study that will include Paxlovid (nirmatrelvir-ritonavir) treatment eligible for people with a positive SARS-CoV-2 diagnostic test and at least one COVID-19 symptom. This study will look at the change in Post Covid Conditions measured by the number of outpatients, Emergency department, urgent care and inpatient visits before and after COVID-19 between those who did and did not receive Paxlovid. In addition, changes in frailty post-acute infection will be evaluated, in a separate analysis. It is hypothesized that individuals with COVID-19 who received Paxlovid will have a smaller post-COVID-19 increase (vs pre-COVID) in PCC healthcare utilization (i.e., cardiopulmonary) in comparison to patients with COVID-19 who did not receive Paxlovid.

Conditions

• COVID-19

Interventions

Type	Name	Description
DRUG	nirmatrelvir-ritonavir	Paxlovid standard of treatment care

Timeline

• Start date: 2025-04-15
• Primary completion: 2025-04-15
• Completion: 2025-04-15
• First posted: 2025-07-29
• Last updated: 2025-07-29

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated drug study